Percutaneous pericardial access for catheter ablation is associated with a bleeding risk. We sought to elucidate the relation of hemorrhagic and thromboembolic events associated with epicardial procedures to anticoagulation strategy.
picardial mapping and ablation is an important therapy for an important number of cardiac arrhythmias, most commonly ventricular tachycardias (VTs) in patients with nonischemic cardiomyopathies. 1 Access to the pericardial space is usually achieved by the percutaneous approach described by Sosa et al. 2 Although endocardial mapping and ablation usually warrant anticoagulation, and anticoagulation is mandatory for mapping in the systemic circulation, the major risk of pericardial access is pericardial bleeding. [3] [4] [5] A recent expert consensus recommended administration of anticoagulants only after pericardial access is established, and absence of bleeding is confirmed. 6 However, the endocardial mapping is often desirable in patients likely to have epicardial arrhythmia targets, some of whom will have successful ablation from the endocardium, potentially sparing them pericardial access. Options for managing anticoagulation during the initial part of the procedure include withholding anticoagulation until after pericardial access is achieved; administering heparin, but reversing it with protamine before attempted pericardial access, or attempting access while the patient is anticoagulated. The relationship between the anticoagulation strategy during pericardial access and complications has not been fully elucidated. The present study compares these strategies.
METHODS
The data, analytic methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Patients
Consecutive patients who underwent their first pericardial access for catheter ablation of ventricular arrhythmia at 2 centers (Brigham and Women's Hospital and Vanderbilt University Medical Center) were included in the study. Patients from Brigham and Women's Hospital underwent these procedures between 2004 and 2017, whereas those from Vanderbilt University Medical Center underwent procedures between 2013 and 2018. All patients gave written informed consent for the procedure. Data collection was conducted in accordance with the protocols approved by the Human Research Committee of each centers. Data were collected from centralized systems containing records of all patients treated and followed at each hospital (Brigham and Women's Hospital and Vanderbilt University Medical Center). The present study overlaps and expands on the population reported from previous studies.
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Procedure Setup
Procedures were performed either under conscious sedation or general anesthesia. Oral antiarrhythmic drugs were discontinued for at least 5 half-lives except for amiodarone. In the patients with ventricular fibrillation storm, intravenous drugs, including antiarrhythmic drugs, were continued until the start of the procedure. Oral anticoagulants were held preoperatively. Bridging with continuous intravenous heparin was done at the discretion of the treating physician, and heparin was discontinued at least 4 hours before the procedure. Oral anticoagulants were resumed after confirmation of the absence of bleeding complication on the next day of the procedure. Oral antiplatelet agents were continued throughout the procedure.
Procedure details have been previously described. 12, 13 In brief, multipolar electrode catheters and an intracardiac ultrasound probe were inserted into the femoral veins. An arterial sheath was placed in a femoral artery with continuous arterial pressure monitoring. Left ventricular (LV) mapping was performed from a retrograde aortic or transatrial septal approach. Electroanatomical mapping and ablation were performed using a 3.5 mm tip open-irrigated catheter (NaviStar ThermoCool series, Biosense Webster, Diamond Bar, CA) or with a 4 mm tip nonirrigated catheter (NaviStar, Biosense Webster) with the CARTO electroanatomic mapping system (CARTO3 or CARTO XP, Biosense Webster).
Epicardial Ablation
Pericardial access was considered if endocardial ablation failed or epicardial arrhythmia origin was suspected. Pericardial access was attempted by 1 of 2 methods. Using an 18 G Touhy needle, the needle was advanced below the xiphoid process under fluoroscopic guidance to the border of the cardiac silhouette. Small volumes of contrast injection were used to identify the pericardium and confirm entry into the pericardial space. A guidewire was placed into the pericardial space, and a long sheath was advanced over the wire. The ablation catheter was then positioned in the pericardial space through the long sheath. 2, 14 
WHAT IS KNOWN?
• A recent expert consensus recommended administration of anticoagulants only after pericardial access is established, and absence of bleeding is confirmed to minimize the risk of pericardial bleeding during epicardial ablation procedures. However, endocardial mapping before the epicardial evaluation is often desirable and requires systemic anticoagulation.
• Three options for managing anticoagulation for epicardial access include withholding anticoagulation until after access is achieved; administering heparin, but reversing it with protamine before attempted access, or attempting access while anticoagulated.
WHAT THE STUDY ADDS?
• In our nonrandomized patient series, there were no differences in risk of pericardial bleeding or embolic events among the 3 anticoagulation strategies.
• Unintentional cardiac puncture is the major risk factor associated with significant pericardial bleeding and methods to reduce this risk are of needed.
was used for the majority of procedures. A 21G micropuncture needle was inserted through a short 18G needle (Cook Medical, Bloomington, IN) and advanced into the pericardial space with location assessed by injection of small amounts of radiographic contrast. A 0.014-inch steel core or Platinum plus (Boston Scientific, Marlborough, MA) guidewire with a floppy tip was then advanced through the inner needle into the pericardial space and a micropuncture dilator advanced into the pericardial space over the guidewire. The guidewire was exchanged for a 0.35-inch wire, and a long steerable sheath (Agilis, St Jude Medical, Minneapolis, MN) was inserted. The mapping or ablation catheter is then advanced to pericardial space. 11 If right ventricular (RV) puncture occurs an attempt is made to withdraw the needle and guidewire into the pericardial space. During the procedure, pericardial fluid is monitored by intracardiac ultrasound and periodic aspiration from the pericardial sheath.
Radiofrequency energy was delivered from the irrigated catheters at a power of 25 to 50 Watts during irrigation at rates of 7 to 30 mL/min targeting an impedance drop of 10 to 20 Ω. Applications at target regions were usually repeated until unipolar pacing at 10 mA at 2 to 9 ms pulse width stimulus strength no longer captured. Coronary angiography was performed before epicardial ablation, and radiofrequency ablation was not applied within 5 mm of major epicardial vessels. Pacing at 10 mA at 2 ms was performed to identify the course of the relevant phrenic nerve. Phrenic nerve protection with a pericardial balloon was used as required.
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Anticoagulation
Warfarin was stopped 3 to 5 days before the procedure with a goal of achieving a prothrombin time international normalized ratio of <1.6 by the day of the procedure. Hospitalization for administration of intravenous heparin during warfarin dissipation was at the discretion of the treating physician. Heparin was stopped at least 4 hours before the procedure. Direct acting oral anticoagulants were generally stopped at least 1 day before the procedure.
The anticoagulation strategy during the ablation procedure was categorized into 3 groups (Figure 1 ). Group 1, no heparin was administered before pericardial access, and the initial part of the study with endocardial RV mapping and ablation was performed without anticoagulation. Group 2, heparin was administered for initial endocardial mapping and ablation and reversed by protamine administration before pericardial access was attempted. The pericardial access was attempted after confirmation of an activated clotting time (ACT) <200 seconds. Group 3, heparin was administered and not reversed for pericardial access. During systemic anticoagulation, heparin was administered intermittently to maintain ACT range between 250 and 350 seconds as checked every 20 to 30 minutes. At the operators' discretion, heparin was reversed by protamine for sheath removal at the end of the procedure. After pericardial access, resumption or continuation of systemic heparin was determined by the absence of pericardial bleeding, and the need for further endocardial mapping and ablation, and anticoagulation was always implemented before any catheter or sheath was inserted into the LV or atrium.
Outcomes
The bleeding events included significant pericardial bleeding (defined as >80 mL), hemoglobin level decrease >2 g/ dL, the requirement for blood transfusion, and groin hematoma requiring therapy or delaying hospital discharge. Thromboembolic events included cerebral infarction or transient ischemic attack, coronary embolism, deep vein thrombosis, and pulmonary embolism.
Statistics
Continuous variables were expressed as mean±SD or median with a range of quartile. The Shapiro-Wilk test was Figure 1 . Anticoagulation strategy groups. Group 1, heparin was not administered before pericardial access. Group 2, heparin was administered and reversed before pericardial access. Group 3, heparin was administered and not reversed before pericardial access. CAG indicates coronary angiography; LV, left ventricle; and RV, right ventricle.
performed for the evaluation of distribution normality. Oneway ANOVA or nonparametric Kruskal-Wallis ANOVA followed by a post hoc analysis with the Bonferroni correction was used to compare continuous variables, depending on whether the values were normally distributed. For categorical data, χ 2 test or Fisher exact test with Bonferroni correction was performed. Univariate and multivariable logistic regression analyses were conducted to identify features associated with pericardial bleeding and cardiac puncture. The factors with P value of <0.1 on univariate analysis were included for multivariable analysis. A P value of <0.05 was considered as statistically significant. All statistical analyses were performed utilizing R software version 3.3.3.
RESULTS
Patient Backgrounds
A total of 355 patients were included. The baseline patient characteristics are summarized in Table 1 . There was a significant difference in the number of prior ablation sessions; 74% of the patients in group 1 had >1 ablation session before the index procedure, whereas 57% in group 2 and 36% in group 3 had prior ablation sessions (P<0.001). The disparity is likely related to a greater proportion of patients in group 1 for whom further endocardial mapping and ablation after their prior procedure were felt not likely to be successful. The use of oral anticoagulants and antiplatelet agents was not different among the groups.
Procedural Characteristics
The procedural findings are shown in Table 2 . The needle-in-needle technique was used for only 21% of the patients in group 1 while it was used ≈50% of the patients in other groups. Reflecting a greater proportion of patients treated before adoption of the needlein-needle technique in group 1. The overall success rate of pericardial access was 94% with no significant difference among the groups (P=0.851). The most common reason for access failure was pericardial adhesions. Unintentional cardiac puncture was observed in 38 cases (11%), and the incidence was not different among the groups (P=0.708). The RV was the most vulnerable site as 34 out 38 cardiac punctures occurred in the RV. The ACTs at the time of the pericardial access differed among the groups (Figure 2 ). In group 2, the median ACT before attempting pericardial access was (Table 2 , no significant differences).
Adverse Events
Adverse events are summarized in Table 3 . Significant pericardial bleeding >80 mL occurred in 46 patients (13%); 13% in group 1, 16% of group 2, and 10% of group 3. There were no statistical differences among groups (P=0.720). A total of 38 patients (11%) had unintentional cardiac puncture recognized. For these 38 patients significant bleeding did not differ among the anticoagulation strategies as it occurred in 18 of 30 patients in group 1 (60%), 3 of 5 in group 2 (60%), and 2 of 3 in group 3 (67%; P=1.000). In those with significant bleeding, 5 patients (11%) required surgical repair.
Thromboembolic complications occurred in 5 patients (2%). In group 1, 3 patients had embolic events: a right common femoral vein thrombus, a left common femoral artery embolism caused by thrombus on a percutaneously inserted LV assist device, and a fatal pulmonary embolism. The pulmonary embolism occurred in a 57-year-old with ischemic cardiomyopathy who had 3 recent prior ablation procedures that had failed. Epicardial ablation was acutely successful and continuous intravenous heparin was reinitiated after the procedure. The following day he suffered massive pulmonary embolism after walking a few steps. One patient in group 2 had coronary thrombosis during coronary angiography after pericardial access. Heparin had been reversed before attempted pericardial access and was not restarted before angiography; inadvertent RV puncture had occurred with significant bleeding that stopped. The left coronary artery was occluded by thrombus resulting in hemodynamic distress; prompt transcatheter thrombectomy and heparinization were followed by immediate recovery with no sequela. One patient in group 3 had a left middle cerebral artery embolism diagnosed immediately after awakening from anesthesia. A dose of 2000 U heparin had been given with initial RV mapping and no protamine administered before pericardial access. Coronary angiography without heparin had been performed during the procedure, and no other left heart catheters had been inserted. On diagnosis of stroke, cerebral angiography and intracerebral thrombolytic therapy and transcatheter recanalization were immediately performed, with partial neurological recovery. There were 2 procedure-related deaths. One patient had pulmonary embolism (above). The second was a 63-year-old male in group 2 with ischemic cardiomyopathy and VT storm. His third ablation procedure was complicated by cardiac tamponade felt to be because of cardiac perforation from an endocardial catheter, which was controlled by heparin reversal and percutaneous drainage that ended the procedure before mapping and ablation were completed. He developed uncontrollable VT storm in the recovery room, severe peripheral atherosclerosis precluded placement of a circulatory assist device.
Patients with and without significant pericardial bleeding are compared in Table 4 . On univariate analysis, LV ejection fraction ≤35%, unintentional cardiac puncture, but not age, sex, body mass index, and anticoagulant usage, was associated with significant bleeding. Nineteen out of 34 patients (56%) with RV puncture developed significant pericardial bleeding. On multivariable analysis, LV ejection fraction ≤35% and cardiac puncture were independently associated with significant pericardial bleeding (odds ratio, 2.28; 95% The predictors of an inadvertent cardiac puncture are shown in Table 5 . Inadvertent cardiac puncture was associated with patient age >55 years (odds ratio, 2.44; 95% CI, 1.07-5.55; P=0.034) and LV ejection fraction ≤35% (odds ratio, 2.67; 95% CI, 1.29-5.53; P=0.005; Table 5 ). Of the 38 patients who had cardiac puncture, pericardial access was established in 31 patients and abandoned in 7 patients. Significant pericardial bleeding occurred in 21 patients (68%) of those in whom access was established and in 2 (29%) of the 7 patients in whom access attempts failed (P=0.0893). Of note, 3 of the 5 patients with failed access who did not develop pericardial bleeding after cardiac puncture had a history of cardiac surgery, and access attempts were abandoned because of pericardial adhesions.
DISCUSSION
Pericardial access has an important role in catheter ablation and for placement of some percutaneous left atrial appendage closure devices. 15 Prior multicenter series have reported a 4% to 11% incidence of complications with a 4% to 5% incidence of pericardial bleeding. 4, 16 Significant pericardial bleeding has been variably defined. In the present series, we used 80 mL as a definition and observed an incidence of 13%, with 5 patients requiring surgical repair. Although there were no fatalities directly related to uncontrolled pericardial bleeding, one patient had fatal VT storm after pericardial bleeding led to an incomplete procedure.
The risk of bleeding is potentially aggravated by the need for anticoagulation during the procedure as combined endocardial and epicardial ablation is often required. The optimal approach to anticoagulation management for these patients is not defined. Holding anticoagulation until after pericardial access is achieved is common but may increase the risk of thromboembolism from venous catheters and is not an option if LV endocardial mapping is performed. We also commonly initiated anticoagulation for initial mapping and when pericardial access was desired, then removed any LV or left atrial catheters, reversed anticoagulation with protamine and then obtained pericardial access. If no bleeding occurred, or after any bleeding had stopped, we then reanticoagulated with heparin if further LV endocardial mapping was desired, or if the procedure was particularly long. Finally, a third option, which we used infrequently, was to obtain pericardial access while the patient was anticoagulated with heparin. This is the most detailed examination of anticoagulation in patients undergoing epicardial mapping with or without ablation. In this study, there was no difference in the risk of bleeding between the groups, supporting the strategy of initial endocardial mapping with anticoagulation with the option of reversing anticoagulation before obtaining pericardial access if desired.
We did not find any significant differences in the risks of bleeding or thromboembolism in comparing these approaches, but there are many caveats and limitations that warrant careful consideration in interpreting this data. This is a retrospective observational study. Although we have a systematic approach, the decision as to which anticoagulation strategy to implement was up to the treating physician and is influenced by many factors. Patients with RV tachycardias often will have initial RV mapping without anticoagulation if pericardial access is felt to be a possibility, as is generally the case, for example, for patients with arrhythmogenic RV cardiomyopathy. Pericardial access is more likely to be anticipated in patients with nonischemic cardiomyopathy and QRS morphologies that are typical for epicardial VTs. Once pericardial access is achieved, reinstituting heparin is influenced by the presence of any pericardial bleeding. A small amount of bleeding is not unusual after pericardial sheath placement. This usually clears rapidly and is monitored continuously with intracardiac ultrasound and frequent aspiration of the pericardial space, which our pericardial sheath allows around the mapping or ablation catheter that is in place. The number of adverse events, particularly thrombotic events were small. It is possible that differences in risk are present among these strategies that may be detected with a larger patient population. The number of patients who had pericardial access placed without reversing anticoagulation was small. We stopped warfarin or direct acting oral anticoagulants before the procedure in all patients, and our findings should not be extrapolated to continuing oral anticoagulation for the pericardial access procedure. Reversing heparin with protamine also has risks, including severe hypotensive reactions. We did not observe this complication, but it would likely emerge in a large cohort. Although we cannot demonstrate association of anticoagulation with bleeding risk, the number of patients in our study is insufficient to determine if the anticoagulation strategy would influence the need for cardiac surgery once bleeding occurred.
Withholding anticoagulation may also be a risk for coronary angiography in these patients who may have an arterial sheath in place for some time before performing angiography. Two of our thromboembolic events were related to coronary angiography done to define proximity of the ablation target to epicardial coronary vessels in patients who were not anticoagulated following pericardial access. Certainly, careful attention to flushing arterial sheaths and catheters and minimizing time in the arterial system is important. The number of events is too small to warrant a clear recommendation as to whether anticoagulation is warranted, as diagnostic angiography does not generally warrant systemic anticoagulation.
Our study also suggests that reversing systemic anticoagulation with protamine before attempting pericardial access is a reasonable approach. Any catheters or sheaths that had been placed in the left heart were always removed before administering protamine. We generally aimed to achieve an ACT of <200 seconds.
The dose of protamine was estimated based on the heparin that had been administered and was at the discretion of the treating physicians.
Not surprisingly, unintentional cardiac puncture seems to be the major cause and risk factor for pericardial bleeding regardless of the anticoagulation strategy. Older age and depressed LV function LV ejection fraction ≤35% were associated risk factors, although the reason for these associations is not certain. The increase in anterior-posterior diameter of the chest and posterior rotation of the heart with age and increase in cardiac size with depressed ventricular function are potential factors.
CONCLUSIONS
Pericardial bleeding is a major risk of epicardial mapping and ablation procedures. Unintentional cardiac puncture is the major risk for significant pericardial bleeding and methods to reduce this risk are of needed. The anticoagulation strategy did not seem to have a major impact on the risk of pericardial bleeding. Although thromboembolic events are infrequent, they do occur and can be severe, supporting use of anticoagulation when it is deemed safe based on lack of pericardial bleeding. 
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